|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
ALK inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:category
|
gptkb:D
not recommended
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
second-line treatment
first-line treatment
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:dosage_form
|
based on body weight
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:formulation
|
gptkb:beer
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ceritinib
|
|
gptkbp:indication
|
gptkb:ALK-positive_metastatic_NSCLC
|
|
gptkbp:ingredients
|
C21 H22 Cl N5 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
L01 X E26
|
|
gptkbp:is_monitored_by
|
cardiac function
electrolytes
liver function tests
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
31 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:price
|
high
|
|
gptkbp:safety_features
|
hepatotoxicity
interstitial lung disease
QT prolongation
embryo-fetal toxicity
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
liver enzyme elevation
thrombocytopenia
visual disturbances
hypersensitivity reactions
pulmonary toxicity
|
|
gptkbp:status
|
ongoing studies
|
|
gptkbp:targets
|
gptkb:anaplastic_lymphoma_kinase_(ALK)
|
|
gptkbp:traded_on
|
gptkb:Zykadia
|
|
gptkbp:type_of
|
1032900-25-6
|
|
gptkbp:type_of_care
|
important
|
|
gptkbp:weight
|
393.95 g/mol
|
|
gptkbp:bfsParent
|
gptkb:ALK
|
|
gptkbp:bfsLayer
|
5
|